Csl Ltd - CSLLY STOCK NEWS

CSL Limited has received all regulatory approvals for the acquisition of Vifor Pharma AG, with settlement set for 9 August 2022. CSL expects to acquire over 97% of Vifor shares post-settlement and plans to delist Vifor. Hervé Gisserot will become General Manager of Vifor upon settlement. CEO Paul Perreault emphasized the acquisition's strategic importance, enhancing CSL's capabilities in rare disease treatment. Vifor's CEO Abbas Hussain expressed confidence in the future within CSL's global framework, allowing for accelerated growth and product launches.

CSL Limited (ASX: CSL; USOTC: CSLLY) announced a further postponement of its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. The settlement, originally set for July 22, 2022, is now extended until September 30, 2022, due to unmet offer conditions regarding merger clearances. This delay follows an initial postponement announced on March 28, 2022. Additionally, CSL has filed for the cancellation of the remaining publicly held Vifor shares.

Seqirus, part of CSL Limited, has commenced shipping its innovative influenza vaccine portfolio for the 2022/23 U.S. season. This includes the first cell-based quadrivalent vaccine, FLUCELVAX®, now available for ages six months and older, and the adjuvanted quadrivalent vaccine FLUAD®, which the CDC recommends for adults aged 65 and older. Seqirus aims to supply over 55 million doses, highlighting the importance of vaccination amidst potential flu resurgence. The CDC notes significant flu-related deaths and hospitalizations, emphasizing vaccination as crucial for public health.

On June 22, 2022, the CDC's ACIP recommended FLUAD® QUADRIVALENT as a preferential flu vaccine for adults 65 and older, emphasizing its clinical benefits over standard vaccines. This recommendation is based on extensive studies showing FLUAD's efficacy in enhancing immune responses, particularly in older populations at higher risk for influenza-related complications. With over 225 million doses distributed globally since its approval, FLUAD aims to protect vulnerable groups from severe illness during the upcoming influenza season.

CSL Behring and photographer Rankin unveil 'Portraits of Progress' in New York City, marking their first in-person exhibit in three years. This multimedia campaign showcases the evolution of hemophilia treatment, from the 1940s to modern gene therapy research. Opening on June 11, 2022, the exhibit features portraits and personal narratives from individuals with hemophilia, highlighting advances in treatment and community hopes for the future. CSL Behring aims to raise awareness of hemophilia and its impact, reinforcing its commitment to innovation in healthcare.

Seqirus, a global influenza vaccine leader under CSL Limited, has completed a $156 million expansion of its manufacturing facility in Holly Springs, N.C. The new line for pre-filled syringes has received FDA approval and will enhance the production of FLUCELVAX® QUADRIVALENT, the only cell-based quadrivalent influenza vaccine in the U.S. The expansion supports over 80 skilled jobs and increases capacity for seasonal vaccines and pandemic readiness. Seqirus aims to respond better to the growing demand for differentiated influenza vaccines.

Seqirus has successfully achieved recognition from the U.S. government for its manufacturing facility in Holly Springs, North Carolina, confirming its capability to produce innovative cell-based seasonal and pandemic influenza vaccines. This facility can deliver 150 million doses within six months of a pandemic declaration. Seqirus previously developed the first adjuvanted, cell-based influenza A(H5N1) vaccine. The Holly Springs site is the largest of its kind globally and is integral to the U.S. pandemic preparedness strategy. Ongoing investments aim to enhance manufacturing capacity and production speed.

The FDA has accepted CSL Behring's Biologics License Application for priority review of etranacogene dezaparvovec, a gene therapy for adults with hemophilia B. This therapy targets the genetic cause of hemophilia B, potentially allowing for near-normal blood clotting. Clinical trials showed a 64% reduction in annual bleeding rates after treatment. Approval could mark the first gene therapy for hemophilia B, enhancing CSL Behring's commitment to innovative treatments for rare diseases. The review process is expected to take six months.

CSL Limited (ASX: CSL; USOTC: CSLLY) announced an update on its acquisition of Vifor Pharma AG, originally expected to close by June 2022. While some antitrust approvals have been received, others are still pending. CSL reassured shareholders that such delays are common and that they are collaborating with remaining authorities for timely resolution. A precise closing date will be communicated once all regulatory approvals are confirmed, and CSL remains confident in finalizing the acquisition.